PMID- 33643916
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210303
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 10
DP  - 2020
TI  - Chaperone Mediated Autophagy Substrates and Components in Cancer.
PG  - 614677
LID - 10.3389/fonc.2020.614677 [doi]
LID - 614677
AB  - Chaperone-mediated autophagy (CMA) represents a specific way of lysosomal protein 
      degradation and contrary to macro and microautophagy is independent of vesicles 
      formation. The role of CMA in different physiopathological processes has been 
      studied for several years. In cancer, alterations of the CMA principal 
      components, Hsc70 and Lamp2A protein and mRNA levels, have been described in 
      malignant cells. However, changes in the expression levels of these CMA 
      components are not always associated with changes in CMA activity and their 
      biological significance must be carefully interpreted case by case. The objective 
      of this review is to discuss whether altering the CMA activity, CMA substrates or 
      CMA components is accurate to avoid cancer progression. In particular, this 
      review will discuss about the evidences in which alterations CMA components 
      Lamp2A and Hsc70 are associated or not with changes in CMA activity in different 
      cancer types. This analysis will help to better understand the role of CMA 
      activity in cancer and to elucidate whether CMA can be considered as target for 
      therapeutics. Further, it will help to define whether the attention of the 
      investigation should be focused on Lamp2A and Hsc70 because they can have an 
      independent role in cancer progression beyond of their participation in altered 
      CMA activity.
CI  - Copyright (c) 2021 Rios, Sequeida, Albornoz and Budini.
FAU - Rios, Javiera
AU  - Rios J
AD  - Molecular and Cellular Pathology Laboratory, Dentistry Faculty, Institute in 
      Dentistry Sciences, University of Chile, Santiago, Chile.
FAU - Sequeida, Alvaro
AU  - Sequeida A
AD  - Molecular and Cellular Pathology Laboratory, Dentistry Faculty, Institute in 
      Dentistry Sciences, University of Chile, Santiago, Chile.
FAU - Albornoz, Amelina
AU  - Albornoz A
AD  - Fundacion Ciencia & Vida, Santiago, Chile.
AD  - San Sebastian University, Santiago, Chile.
FAU - Budini, Mauricio
AU  - Budini M
AD  - Molecular and Cellular Pathology Laboratory, Dentistry Faculty, Institute in 
      Dentistry Sciences, University of Chile, Santiago, Chile.
AD  - Autophagy Research Center (ARC), Santiago, Chile.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210212
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC7908825
OTO - NOTNLM
OT  - CMA
OT  - autophagy
OT  - cancer progression
OT  - oncogenic protein
OT  - tumor suppressor
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/03/02 06:00
MHDA- 2021/03/02 06:01
PMCR- 2020/01/01
CRDT- 2021/03/01 05:38
PHST- 2020/10/06 00:00 [received]
PHST- 2020/12/14 00:00 [accepted]
PHST- 2021/03/01 05:38 [entrez]
PHST- 2021/03/02 06:00 [pubmed]
PHST- 2021/03/02 06:01 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2020.614677 [doi]
PST - epublish
SO  - Front Oncol. 2021 Feb 12;10:614677. doi: 10.3389/fonc.2020.614677. eCollection 
      2020.